Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B ...

New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials.

Dynavax Technologies Corporation's flagship product, Heplisav-B, continues to increase market share consistently in a growing ...

Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company ...

A study published in 2023 highlights significant discoveries that were only made possible through DNA analysis of Beethoven’s hair.

The researchers conducted a cohort study using data from more than 6 million adults from the Veterans Health Administration ...

Arbutus has moved into Part 3 of this clinical trial which evaluates repeat dosing of AB-101 for 28 days in patients with cHBV and expects to report preliminary data in the first half of next year.

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

This study aimed to analyze and compare the epidemiological trends of liver cancer attributed to hepatitis B (LCHB) and alcohol use (LCAL) over the past 32 years. Data on mortality and ...

As Louisiana’s rate of fully vaccinated children slips as part of blowback related to the COVID-19 pandemic, health care ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

LAHORE: In what appeared to be a distressing incident, a kidney-failure patient died while 30 others contracted Human ...